

# Manuel Battegay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5572584/publications.pdf>

Version: 2024-02-01

355  
papers

15,609  
citations

20817

60  
h-index

24982

109  
g-index

369  
all docs

369  
docs citations

369  
times ranked

17320  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. <i>Clinical Infectious Diseases</i> , 2022, 74, 1468-1475.	5.8	3
2	Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 579-584.	4.7	15
3	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2022, 51, 33-34j.	1.9	69
4	Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 492-499.	3.0	7
5	Exercise capacity impairment after COVID-19 pneumonia is mainly caused by deconditioning. <i>European Respiratory Journal</i> , 2022, 59, 2101136.	6.7	24
6	Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1592-1600.	4.0	4
7	A qualitative study on safety perception among healthcare workers of a tertiary academic care center during the SARS-CoV-2 pandemic. <i>Antimicrobial Resistance and Infection Control</i> , 2022, 11, 30.	4.1	4
8	Determinants of SARS-CoV-2 transmission to guide vaccination strategy in an urban area. <i>Virus Evolution</i> , 2022, 8, veac002.	4.9	7
9	Impact of Latent Tuberculosis on Diabetes. <i>Journal of Infectious Diseases</i> , 2022, 225, 2229-2234.	4.0	3
10	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	2.1	0
11	Failure to return pillbox is a predictor of being lost to follow-up among people living with HIV on antiretroviral therapy in rural Tanzania. <i>HIV Medicine</i> , 2022, 23, 661-672.	2.2	5
12	SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination. <i>Microorganisms</i> , 2022, 10, 857.	3.6	8
13	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. <i>Haematologica</i> , 2021, 106, 2233-2241.	3.5	4
14	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021, 73, 195-202.	5.8	8
15	Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors. <i>Clinical Infectious Diseases</i> , 2021, 73, e2145-e2152.	5.8	9
16	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2021, 72, 2175-2183.	5.8	10
17	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1413-1421.	5.8	2
18	Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 458-470.	2.4	12

#	ARTICLE	IF	CITATIONS
19	Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug–Drug Interaction Magnitudes in the Elderly. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 471-484.	4.7	10
20	Mortality Rate in a Cohort of People Living With HIV in Rural Tanzania After Accounting for Unseen Deaths Among Those Lost to Follow-up. <i>American Journal of Epidemiology</i> , 2021, 190, 251-264.	3.4	8
21	Epidemiology and precision of SARS-CoV-2 detection following lockdown and relaxation measures. <i>Journal of Medical Virology</i> , 2021, 93, 2374-2384.	5.0	20
22	Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19. <i>Drug Safety</i> , 2021, 44, 255-257.	3.2	1
23	Prescribing in COVID-19 patients: Should we take into account inflammation?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 719-721.	2.4	0
24	Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia. <i>Journal of Intensive Care</i> , 2021, 9, 10.	2.9	52
25	Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. <i>Nature Communications</i> , 2021, 12, 6.	12.8	164
26	Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1025-1029.	4.7	8
27	Systematic screening on admission for SARS-CoV-2 to detect asymptomatic infections. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 44.	4.1	17
28	Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1231-1239.	4.7	13
29	HIV-Infected Patients Developing Tuberculosis Disease Show Early Changes in the Immune Response to Novel Mycobacterium tuberculosis Antigens. <i>Frontiers in Immunology</i> , 2021, 12, 620622.	4.8	7
30	SARS-CoV-2 outbreak in a tri-national urban area is dominated by a B.1 lineage variant linked to a mass gathering event. <i>PLoS Pathogens</i> , 2021, 17, e1009374.	4.7	36
31	Immunophenotypic characterization of TCR $\beta$ T cells and MAIT cells in HIV-infected individuals developing Hodgkin's lymphoma. <i>Infectious Agents and Cancer</i> , 2021, 16, 24.	2.6	3
32	Response to a sexual risk reduction intervention provided in combination with hepatitis C treatment by HIV/HCV co-infected men who have sex with men: a reflexive thematic analysis. <i>BMC Infectious Diseases</i> , 2021, 21, 319.	2.9	11
33	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021, 35, 2025-2033.	2.2	4
34	Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance. <i>Microorganisms</i> , 2021, 9, 1094.	3.6	21
35	Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link. <i>ELife</i> , 2021, 10, .	6.0	3
36	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ $\mu$ L. <i>Journal of the International AIDS Society</i> , 2021, 24, e25726.	3.0	8

#	ARTICLE	IF	CITATIONS
37	Temporal trends of COVID-19 related in-hospital mortality and demographics in Switzerland – a retrospective single centre cohort study. <i>Swiss Medical Weekly</i> , 2021, 151, w20572.	1.6	16
38	Recognition and management of clinically significant drug–drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2681-2689.	3.0	2
39	Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab – a single centre cohort study. <i>Swiss Medical Weekly</i> , 2021, 151, w20550.	1.6	6
40	Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient – a case report and review of the literature. <i>AIDS Research and Therapy</i> , 2021, 18, 56.	1.7	4
41	Comparing Immunoassays for SARS-CoV-2 Antibody Detection in Patients with and without Laboratory-Confirmed SARS-CoV-2 Infection. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0138121.	3.9	16
42	Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab032.	0.9	16
43	Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 758-764.	3.0	14
44	Offering ART refill through community health workers versus clinic-based follow-up after home-based same-day ART initiation in rural Lesotho: The VIBRA cluster-randomized clinical trial. <i>PLoS Medicine</i> , 2021, 18, e1003839.	8.4	8
45	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. <i>PLoS Computational Biology</i> , 2021, 17, e1009529.	3.2	6
46	Long-term outcome after SARS-CoV-2 infection in healthcare workers: a single centre cohort study. <i>Swiss Medical Weekly</i> , 2021, 151, w30094.	1.6	8
47	Evolution of COVID-19 mortality over time: results from the Swiss hospital surveillance system (CH-SUR). <i>Swiss Medical Weekly</i> , 2021, 151, w30105.	1.6	16
48	Morbidity associated with <i>Schistosoma mansoni</i> infection in north-eastern Democratic Republic of the Congo. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009375.	3.0	3
49	Epidemiology of <i>Schistosoma mansoni</i> infection in Ituri Province, north-eastern Democratic Republic of the Congo. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009486.	3.0	3
50	Corrigendum to: Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired Respiratory Viruses. <i>Journal of Infectious Diseases</i> , 2021, 223, 734-735.	4.0	1
51	Prevalence, incidence and predictors of renal impairment in persons with HIV receiving protease-inhibitors in rural Tanzania. <i>PLoS ONE</i> , 2021, 16, e0261367.	2.5	3
52	Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. <i>Clinical Pharmacokinetics</i> , 2020, 59, 383-401.	3.5	29
53	Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction. <i>International Journal of Cancer</i> , 2020, 147, 757-765.	5.1	5
54	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. <i>Aids</i> , 2020, 34, 103-108.	2.2	18

#	ARTICLE	IF	CITATIONS
55	COVID-19 Triage and Test Center: Safety, Feasibility, and Outcomes of Low-Threshold Testing. <i>Journal of Clinical Medicine</i> , 2020, 9, 3217.	2.4	9
56	Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial. <i>BMJ Open</i> , 2020, 10, e040110.	1.9	5
57	Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired Respiratory Viruses. <i>Journal of Infectious Diseases</i> , 2020, 222, 1270-1279.	4.0	64
58	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 517-524.	2.1	7
59	Home-based oral self-testing for absent and declining individuals during a door-to-door HIV testing campaign in rural Lesotho (HOSENG): a cluster-randomised trial. <i>Lancet HIV</i> , 2020, 7, e752-e761.	4.7	21
60	Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho. <i>PLoS Medicine</i> , 2020, 17, e1003325.	8.4	16
61	Are three antiseptic paints needed for safe preparation of the surgical field? A prospective cohort study with 239 patients. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 120.	4.1	4
62	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. <i>Nature Communications</i> , 2020, 11, 5542.	12.8	5
63	Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled two-center study. <i>BMC Infectious Diseases</i> , 2020, 20, 349.	2.9	6
64	Low rates of active hepatitis B and C infections among adults and children living with HIV and taking antiretroviral therapy: A multicenter screening study in Lesotho. <i>Journal of Medical Virology</i> , 2020, 92, 3857-3861.	5.0	1
65	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 224, 1198-1208.	4.0	5
66	Low rates of influenza vaccination uptake among healthcare workers: Distinguishing barriers between occupational groups. <i>American Journal of Infection Control</i> , 2020, 48, 1139-1143.	2.3	16
67	Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3084-3086.	3.0	43
68	Prospective assessment of loss to follow-up: incidence and associated factors in a cohort of HIV-positive adults in rural Tanzania. <i>Journal of the International AIDS Society</i> , 2020, 23, e25460.	3.0	18
69	Extrapulmonary tuberculosis in HIV-infected patients in rural Tanzania: The prospective Kilombero and Ulanga antiretroviral cohort. <i>PLoS ONE</i> , 2020, 15, e0229875.	2.5	9
70	Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa185.	0.9	44
71	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	50
72	High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania – A prospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0227600.	2.5	8

#	ARTICLE	IF	CITATIONS
73	Repeated Syphilis Episodes in HIV-Infected Men Who Have Sex With Men: A Multicenter Prospective Cohort Study on Risk Factors and the Potential Role of Syphilis Immunity. Open Forum Infectious Diseases, 2020, 7, ofaa019.	0.9	18
74	Real-life management of drug-drug interactions between antiretrovirals and statins. Journal of Antimicrobial Chemotherapy, 2020, 75, 1972-1980.	3.0	8
75	Aging does not impact drug-drug interaction magnitudes with antiretrovirals. Aids, 2020, 34, 949-952.	2.2	2
76	Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study. Blood, 2020, 136, 29-30.	1.4	6
77	Characterising the epidemic spread of influenza A/H3N2 within a city through phylogenetics. PLoS Pathogens, 2020, 16, e1008984.	4.7	17
78	2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate – a word of caution. Swiss Medical Weekly, 2020, 150, w20203.	1.6	135
79	COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. Swiss Medical Weekly, 2020, 150, w20225.	1.6	367
80	Reproductive number of the COVID-19 epidemic in Switzerland with a focus on the Cantons of Basel-Stadt and Basel-Landschaft. Swiss Medical Weekly, 2020, 150, w20271.	1.6	64
81	Early off-label treatment during pandemics? A dilemma. Swiss Medical Weekly, 2020, 150, w20281.	1.6	3
82	Schistosomiasis: from established diagnostic assays to emerging micro/nanotechnology-based rapid field testing for clinical management and epidemiology. Precision Nanomedicine, 2020, 3, 439-458.	0.8	7
83	Title is missing!., 2020, 17, e1003325.		0
84	Title is missing!., 2020, 17, e1003325.		0
85	Title is missing!., 2020, 17, e1003325.		0
86	Title is missing!., 2020, 17, e1003325.		0
87	Title is missing!., 2020, 15, e0229875.		0
88	Title is missing!., 2020, 15, e0229875.		0
89	Title is missing!., 2020, 15, e0229875.		0
90	Title is missing!., 2020, 15, e0229875.		0

#	ARTICLE	IF	CITATIONS
91	Title is missing!. , 2020, 15, e0229875.		0
92	Title is missing!. , 2020, 15, e0229875.		0
93	SPHN/PHRT: Forming a Swiss-Wide Infrastructure for Data-Driven Sepsis Research. Studies in Health Technology and Informatics, 2020, 270, 1163-1167.	0.3	3
94	Plea for Standardized Reporting and Justification of Propensity Score Methods. Clinical Infectious Diseases, 2019, 68, 710-711.	5.8	3
95	Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2019, 68, 827-833.	5.8	7
96	Impact of health insurance status on surgical site infection incidence: A prospective cohort study. Infection Control and Hospital Epidemiology, 2019, 40, 1063-1065.	1.8	0
97	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nature Communications, 2019, 10, 3193.	12.8	112
98	Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis. BMC Infectious Diseases, 2019, 19, 821.	2.9	8
99	Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. Mycoses, 2019, 62, 1127-1132.	4.0	13
100	Safety and tolerance of lymph node biopsies from chronic HIV-1 volunteers in rural Tanzania. BMC Research Notes, 2019, 12, 561.	1.4	0
101	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. Journal of Viral Hepatitis, 2019, 26, 1224-1228.	2.0	15
102	Sonography to Rule Out Tuberculosis in Sub-Saharan Africa: A Prospective Observational Study. Open Forum Infectious Diseases, 2019, 6, ofz154.	0.9	15
103	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet, The, 2019, 393, 2428-2438.	13.7	627
104	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. Journal of Infectious Diseases, 2019, 220, 244-253.	4.0	6
105	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. Journal of Infectious Diseases, 2019, 220, 254-265.	4.0	27
106	Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. Open Forum Infectious Diseases, 2019, 6, ofz531.	0.9	38
107	Age-related comorbidities and mortality in people living with HIV in rural Tanzania. Aids, 2019, 33, 1031-1041.	2.2	18
108	HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 508-515.	2.1	0



#	ARTICLE	IF	CITATIONS
109	Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes. <i>Clinical Pharmacokinetics</i> , 2019, 58, 483-501.	3.5	48
110	High Mortality of Non-Fournier Necrotizing Fasciitis With Enterobacteriales: Time to Rethink Classification?. <i>Clinical Infectious Diseases</i> , 2019, 69, 147-150.	5.8	9
111	Frequent Door Openings During Cardiac Surgery Are Associated With Increased Risk for Surgical Site Infection: A Prospective Observational Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 290-294.	5.8	26
112	Identification of influenza urban transmission patterns by geographical, epidemiological and whole genome sequencing data: protocol for an observational study. <i>BMJ Open</i> , 2019, 9, e030913.	1.9	7
113	The rate of mother-to-child transmission of antiretroviral drug-resistant HIV strains is low in the Swiss Mother and Child HIV Cohort Study. <i>Swiss Medical Weekly</i> , 2019, 149, w20059.	1.6	4
114	Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	17
115	Prevalence and Evolution of Renal Impairment in People Living With HIV in Rural Tanzania. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy072.	0.9	9
116	Digging Out the Evidence—How Strong Is the IDSA Recommendation Against Antibiotic Prophylaxis in Basilar Skull Fracture and Cerebrospinal Fluid Leakage?. <i>Clinical Infectious Diseases</i> , 2018, 66, 1319-1320.	5.8	2
117	Direct Costs of a Contact Isolation Day: A Prospective Cost Analysis at a Swiss University Hospital. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 101-103.	1.8	28
118	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , 2018, 110, 598-607.	6.3	12
119	Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in the early and late postgastric bypass surgery periods. <i>Aids</i> , 2018, 32, 1903-1905.	2.2	7
120	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. <i>Virus Evolution</i> , 2018, 4, vey024.	4.9	17
121	Introduction to Machine Learning in Digital Healthcare Epidemiology. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 1457-1462.	1.8	51
122	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. <i>Molecular Biology and Evolution</i> , 2018, 35, 27-37.	8.9	37
123	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. <i>Nature</i> , 2018, 561, 406-410.	27.8	47
124	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018, 215, 1589-1608.	8.5	29
125	Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study. <i>Kidney International Reports</i> , 2018, 3, 1089-1099.	0.8	4
126	Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2729-2737.	3.0	16



#	ARTICLE	IF	CITATIONS
127	Costs versus earnings in colon surgery and coronary artery bypass grafting under a prospective payment system: Sufficient financial incentives to reduce surgical site infections?. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 1246-1249.	1.8	2
128	Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. <i>Hematological Oncology</i> , 2018, 36, 757-764.	1.7	4
129	Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2574-2577.	3.0	8
130	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1275-1278.	5.8	23
131	Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2069-2074.	3.0	11
132	Specificity of two HIV screening tests detecting simultaneously HIV-1 p24 antigen and antibodies to HIV-1 and $\alpha^2$ . <i>Journal of Virological Methods</i> , 2017, 249, 143-146.	2.1	8
133	Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. <i>Medicine (United States)</i> , 2017, 96, e5849.	1.0	36
134	Dolutegravir plasma levels after gastric bypass surgery. <i>Aids</i> , 2017, 31, 1052-1054.	2.2	8
135	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017, 66, 297-303.	3.7	101
136	Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. <i>Clinical Pharmacokinetics</i> , 2017, 56, 409-420.	3.5	18
137	Previous exposure in a high-risk area for travellers' diarrhoea within the past year is associated with a significant protective effect for travellers' diarrhoea: a prospective observational cohort study in travellers to South Asia. <i>Journal of Travel Medicine</i> , 2017, 24, .	3.0	10
138	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. <i>ELife</i> , 2017, 6, .	6.0	16
139	Increasing prevalence of infectious diseases in asylum seekers at a tertiary care hospital in Switzerland. <i>PLoS ONE</i> , 2017, 12, e0179537.	2.5	26
140	A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. <i>PLoS ONE</i> , 2017, 12, e0180983.	2.5	29
141	Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2017, 17, 476.	2.9	8
142	Prevention of mother-to-child transmission of HIV Option B+ cascade in rural Tanzania: The One Stop Clinic model. <i>PLoS ONE</i> , 2017, 12, e0181096.	2.5	29
143	Incidence and risk factors for hypertension among HIV patients in rural Tanzania - A prospective cohort study. <i>PLoS ONE</i> , 2017, 12, e0172089.	2.5	53
144	The Model for End-stage Liver Disease (MELD) as a predictor of short-term mortality in <i>Staphylococcus aureus</i> bloodstream infection: A single-centre observational study. <i>PLoS ONE</i> , 2017, 12, e0175669.	2.5	5

#	ARTICLE	IF	CITATIONS
145	Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) - A prospective HIV cohort in rural Tanzania. <i>Swiss Medical Weekly</i> , 2017, 147, w14485.	1.6	27
146	Value of the Pitt Bacteraemia Score to predict short-term mortality in <i>Staphylococcus aureus</i> bloodstream infection: a validation study. <i>Swiss Medical Weekly</i> , 2017, 147, w14482.	1.6	8
147	Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naïve Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw162.	0.9	18
148	Standard Genotyping Overestimates Transmission of <i>Mycobacterium tuberculosis</i> among Immigrants in a Low-Incidence Country. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1862-1870.	3.9	94
149	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 399-402.	4.0	47
150	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	5.8	20
151	Determinants of HIV-1 broadly neutralizing antibody induction. <i>Nature Medicine</i> , 2016, 22, 1260-1267.	30.7	133
152	Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. <i>Hepatology</i> , 2016, 64, 1856-1869.	7.3	82
153	Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared. <i>International Journal of Infectious Diseases</i> , 2016, 51, 97-102.	3.3	18
154	Low-Dose Acetylsalicylic Acid Treatment and Impact on Short-Term Mortality in <i>Staphylococcus aureus</i> Bloodstream Infection. <i>Critical Care Medicine</i> , 2016, 44, 773-781.	0.9	22
155	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 821-829.	5.8	48
156	Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis. <i>Journal of Infectious Diseases</i> , 2016, 214, 599-606.	4.0	34
157	Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw022.	0.9	15
158	A Case Series of Acquired Drug Resistance-Associated Mutations in Human Immunodeficiency Virus-Infected Children: An Emerging Public Health Concern in Rural Africa. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv199.	0.9	3
159	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	3.0	4
160	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1310-1317.	5.8	52
161	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 115-122.	5.8	60
162	Ebola vaccination. <i>Lancet</i> , The, 2015, 386, 2478-2480.	13.7	0

#	ARTICLE	IF	CITATIONS
163	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv108.	0.9	38
164	HIV resistance testing and detected drug resistance in Europe. <i>Aids</i> , 2015, 29, 1379-1389.	2.2	12
165	Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. <i>Aids</i> , 2015, 29, 2195-2200.	2.2	58
166	The HIV care cascade in Switzerland. <i>Aids</i> , 2015, 29, 2509-2515.	2.2	72
167	Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , 2015, 18, 20317.	3.0	52
168	A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. <i>PLoS ONE</i> , 2015, 10, e0123275.	2.5	23
169	Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 391-396.	3.3	15
170	Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv046.	0.9	68
171	Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. <i>BMC Infectious Diseases</i> , 2015, 15, 382.	2.9	29
172	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015, 212, 28-38.	4.0	61
173	Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma. <i>International Journal of STD and AIDS</i> , 2015, 26, 212-214.	1.1	5
174	The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2015, 212, 578-584.	4.0	20
175	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naïve adults. <i>Aids</i> , 2015, 29, 193-200.	2.2	13
176	HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. <i>BMC Gastroenterology</i> , 2015, 15, 79.	2.0	18
177	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv257.	3.0	6
178	T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells. <i>Cytotherapy</i> , 2015, 17, 1280-1291.	0.7	11
179	A Diagnostic HIV-1 Tropism System Based on Sequence Relatedness. <i>Journal of Clinical Microbiology</i> , 2015, 53, 597-610.	3.9	8
180	Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 467-477.	2.0	8

#	ARTICLE	IF	CITATIONS
181	Limitations in Study on Benefits of Clindamycin. <i>Clinical Infectious Diseases</i> , 2015, 60, 323-323.	5.8	1
182	Disseminated tuberculosis in an HIV-infected child: rifampicin resistance detected by GeneXpert in a lymph node aspirate but not in cerebrospinal fluid. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014207997.	0.5	1
183	Acute kidney injury KDIGO stage 2 to 3 in HIV-positive patients treated with cART – a case series over 11 years in a cohort of 1,153 patients. <i>Swiss Medical Weekly</i> , 2015, 145, w14135.	1.6	6
184	Choice of initial therapy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19488.	3.0	2
185	Disentangling Human Tolerance and Resistance Against HIV. <i>PLoS Biology</i> , 2014, 12, e1001951.	5.6	53
186	IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza. <i>PLoS Pathogens</i> , 2014, 10, e1004556.	4.7	108
187	A short tool to screen HIV-infected patients for mild neurocognitive disorders – a pilot study. <i>BMC Psychology</i> , 2014, 2, 21.	2.1	6
188	Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. <i>Aids</i> , 2014, 28, 2565-2571.	2.2	9
189	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 285-294.	5.8	75
190	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. <i>International Journal of Epidemiology</i> , 2014, 43, 887-896.	1.9	36
191	Vaccine adjuvants – understanding molecular mechanisms to improve vaccines. <i>Swiss Medical Weekly</i> , 2014, 144, w13940.	1.6	24
192	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. <i>Journal of Infectious Diseases</i> , 2014, 210, 1555-1561.	4.0	16
193	Co-Trimoxazole Prophylaxis Is Associated with Reduced Risk of Incident Tuberculosis in Participants in the Swiss HIV Cohort Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2363-2368.	3.2	34
194	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	5.8	140
195	Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir. <i>Clinical Infectious Diseases</i> , 2014, 59, 1420-1428.	5.8	4
196	Does HIV antiretroviral therapy still need its backbone?. <i>Lancet, The</i> , 2014, 384, 1908-1910.	13.7	4
197	Virologic and Immunologic Responses in Treatment-Naive Patients to Ritonavir-Boosted Atazanavir or Efavirenz With a Common Backbone. <i>HIV Clinical Trials</i> , 2014, 15, 92-103.	2.0	4
198	Surgical and Antimicrobial Treatment of Prosthetic Vascular Graft Infections at Different Surgical Sites: A Retrospective Study of Treatment Outcomes. <i>PLoS ONE</i> , 2014, 9, e112947.	2.5	69

#	ARTICLE	IF	CITATIONS
199	Enterococci, Clostridium difficile and ESBL-producing bacteria: epidemiology, clinical impact and prevention in ICU patients. Swiss Medical Weekly, 2014, 144, w14009.	1.6	22
200	Symptom manageability in Swiss HIV-infected patients. Applied Nursing Research, 2013, 26, 110-115.	2.2	4
201	The Brain Entry of HIV-1 Protease Inhibitors Is Facilitated When Used in Combination. Molecular Pharmaceutics, 2013, 10, 2340-2349.	4.6	20
202	The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients. PLoS Computational Biology, 2013, 9, e1003203.	3.2	19
203	HIV Infection Disrupts the Sympatric Host-Pathogen Relationship in Human Tuberculosis. PLoS Genetics, 2013, 9, e1003318.	3.5	78
204	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count $\geq 200$ Cells/ $\mu$ L in the Post-Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	5.8	92
205	Viral Hepatitis and Rapid Diagnostic Test Based Screening for HBsAg in HIV-infected Patients in Rural Tanzania. PLoS ONE, 2013, 8, e58468.	2.5	36
206	Low Levels of Mannan-Binding Lectin or Ficolins Are Not Associated with an Increased Risk of Cytomegalovirus Disease in HIV-Infected Patients. PLoS ONE, 2013, 8, e51983.	2.5	8
207	Uptake of guidelines on prevention of mother-to-child transmission of HIV in rural Tanzania: time for change. Swiss Medical Weekly, 2013, 143, w13775.	1.6	16
208	Role of retroviral restriction factors in the interferon- $\lambda$ -mediated suppression of HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3035-3040.	7.1	129
209	Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations. Clinical Infectious Diseases, 2012, 54, 131-140.	5.8	32
210	Mycobacterium tuberculosis Transmission in a Country with Low Tuberculosis Incidence: Role of Immigration and HIV Infection. Journal of Clinical Microbiology, 2012, 50, 388-395.	3.9	41
211	Beneficial course of two cases of HIV-associated multicentric Castleman disease treated with HIV antiretroviral therapy. Aids, 2012, 26, 1449-1450.	2.2	2
212	Lung Resection in Hematologic Patients With Pulmonary Invasive Fungal Disease. Chest, 2012, 142, 988-995.	0.8	17
213	Efavirenz in an Obese HIV-Infected Patient - a Report and An <i>In Vitro</i> <i>In Vivo</i> Extrapolation Model Indicate Risk of Underdosing. Antiviral Therapy, 2012, 17, 1381-1384.	1.0	15
214	Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. Aids, 2012, 26, 567-575.	2.2	68
215	No Risk of Surgical Site Infections From Residual Bacteria After Disinfection With Povidone-Iodine-Alcohol in 1014 Cases. Annals of Surgery, 2012, 255, 565-569.	4.2	29
216	Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. PLoS ONE, 2012, 7, e29186.	2.5	21

#	ARTICLE	IF	CITATIONS
217	Genetic Diversity of EBV-Encoded LMP1 in the Swiss HIV Cohort Study and Implication for NF- $\kappa$ B Activation. PLoS ONE, 2012, 7, e32168.	2.5	20
218	Emergence of Glutaraldehyde-Resistant <i>Pseudomonas aeruginosa</i> . Infection Control and Hospital Epidemiology, 2011, 32, 1173-1178.	1.8	25
219	A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA. PLoS ONE, 2011, 6, e27903.	2.5	21
220	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. Antiviral Therapy, 2011, 16, 535-545.	1.0	77
221	Bioavailability of Extended-Release Nevirapine 400 and 300 mg in HIV-1: A Multicenter, Open-Label Study. Clinical Therapeutics, 2011, 33, 1308-1320.	2.5	10
222	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology, 2011, 53, 1446-1454.	7.3	56
223	The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. Journal of Infectious Diseases, 2011, 204, 1095-1103.	4.0	74
224	Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. Aids, 2011, 25, 441-451.	2.2	34
225	Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 2011, 66, 2107-2111.	3.0	131
226	Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut, 2011, 60, 1506-1519.	12.1	60
227	Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2011, 53, 1130-1139.	5.8	525
228	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. Clinical Infectious Diseases, 2011, 52, 532-539.	5.8	127
229	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. Journal of Clinical Investigation, 2011, 121, 2391-2400.	8.2	168
230	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. PLoS ONE, 2011, 6, e27463.	2.5	46
231	Virosomal influenza-vaccine induced immunity in HIV-infected individuals with high versus low CD4+ T-cell counts: clues towards a rational vaccination strategy. Aids, 2010, 24, 2287-2289.	2.2	9
232	HIV-positive child with epidermodysplasia verruciformis-like lesions and homozygous mutation in TMC6. Aids, 2010, 24, 2758-2760.	2.2	5
233	Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 2010, 15, 413-423.	1.0	172
234	Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. Antiviral Therapy, 2010, 15, 31-40.	1.0	12



#	ARTICLE	IF	CITATIONS
235	Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania. <i>Tropical Medicine and International Health</i> , 2010, 15, 567-573.	2.3	21
236	A rifampicin-containing antibiotic treatment improves outcome of staphylococcal deep sternal wound infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1799-1806.	3.0	37
237	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. <i>Gut</i> , 2010, 59, 1252-1258.	12.1	46
238	Low Postseroconversion CD4 Count and Rapid Decrease of CD4 Density Identify HIV <sup>+</sup> Fast Progressors. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 997-1005.	1.1	9
239	Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-infection. <i>Clinical Infectious Diseases</i> , 2010, 50, 502-511.	5.8	88
240	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. <i>PLoS Pathogens</i> , 2010, 6, e1001123.	4.7	108
241	Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy?. <i>Aids</i> , 2010, 24, 1057-1059.	2.2	3
242	Suicide in HIV-Infected Individuals and the General Population in Switzerland, 1988-2008. <i>American Journal of Psychiatry</i> , 2010, 167, 143-150.	7.2	104
243	Extended Spectrum $\beta$ -Lactamase-producing <i>Escherichia coli</i> in Neonatal Care Unit. <i>Emerging Infectious Diseases</i> , 2010, 16, 1758-1760.	4.3	41
244	JC Virus-Specific Immune Responses in Human Immunodeficiency Virus Type 1 Patients with Progressive Multifocal Leukoencephalopathy. <i>Journal of Virology</i> , 2009, 83, 4404-4411.	3.4	74
245	Incidence and Outcome of Progressive Multifocal Leukoencephalopathy over 20 Years of the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2009, 48, 1459-1466.	5.8	123
246	Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 48, 979-987.	5.8	43
247	Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 621-628.	5.1	38
248	Drug-Drug Interaction in a Kidney Transplant Recipient Receiving HIV Salvage Therapy and Tacrolimus. <i>American Journal of Kidney Diseases</i> , 2009, 54, e1-e4.	1.9	43
249	Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 632-641.	5.0	14
250	Outcomes of early switching from intravenous to oral antibiotics on medical wards. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 188-199.	3.0	128
251	Scabies Outbreak in an Intensive Care Unit with 1,659 Exposed Individuals-Key Factors for Controlling the Outbreak. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 354-360.	1.8	50
252	A Pain in the Neck: Probiotics for Ulcerative Colitis. <i>Annals of Internal Medicine</i> , 2009, 151, 895.	3.9	13



#	ARTICLE	IF	CITATIONS
253	Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. <i>Antiviral Therapy</i> , 2009, 14, 771-779.	1.0	9
254	Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals. <i>HIV Clinical Trials</i> , 2009, 10, 207-214.	2.0	3
255	Hodgkin lymphoma in the Swiss HIV Cohort Study. <i>Blood</i> , 2009, 113, 5737-5742.	1.4	92
256	Safety and Efficacy of Once-Daily Nevirapine Dosing: A Multicohort Study. <i>Antiviral Therapy</i> , 2009, 14, 931-938.	1.0	20
257	Impact of Previous Virological Treatment Failures and Adherence on the Outcome of Antiretroviral Therapy in 2007. <i>PLoS ONE</i> , 2009, 4, e8275.	2.5	18
258	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2009, 14, 349-357.	1.0	45
259	Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. <i>European Journal of Immunology</i> , 2008, 38, 2665-2677.	2.9	138
260	Round-table multidisciplinary counselling of couples with HIV prior to assisted reproduction. <i>Reproductive BioMedicine Online</i> , 2008, 17, 167-174.	2.4	6
261	Characteristics and Treatment Outcome of Cerebrospinal Fluid Shunt-Associated Infections in Adults: A Retrospective Analysis over an 11-Year Period. <i>Clinical Infectious Diseases</i> , 2008, 47, 73-82.	5.8	226
262	Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. <i>Aids</i> , 2008, 22, 301-306.	2.2	124
263	Durability and Outcome of Initial Antiretroviral Treatments Received during 2000-2005 by Patients in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2008, 197, 1685-1694.	4.0	95
264	Factors Associated with the Emergence of K65R in Patients with HIV-1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1299-1309.	5.8	35
265	Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 46, 1921-1925.	5.8	28
266	CD4 <sup>+</sup> T Cell Count Recovery in HIV Type 1-Infected Patients Is Independent of Class of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 47, 1093-1101.	5.8	46
267	Antiretroviral therapy of late presenters with advanced HIV disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 41-44.	3.0	130
268	Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. <i>Aids</i> , 2008, 22, 767-775.	2.2	48
269	Response to combination antiretroviral therapy: variation by age. <i>Aids</i> , 2008, 22, 1463-1473.	2.2	188
270	Self-Reported Non-Adherence to Antiretroviral Therapy Repeatedly assessed by Two Questions Predicts Treatment Failure in Virologically Suppressed Patients. <i>Antiviral Therapy</i> , 2008, 13, 77-86.	1.0	100

#	ARTICLE	IF	CITATIONS
271	HIV Patients Developing Primary CNS Lymphoma Lack EBV-Specific CD4+ T Cell Function Irrespective of Absolute CD4+ T Cell Counts. <i>PLoS Medicine</i> , 2007, 4, e96.	8.4	81
272	Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. <i>Aids</i> , 2007, 21, 1977-1980.	2.2	19
273	Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. <i>Aids</i> , 2007, 21, 939-946.	2.2	30
274	Ecological Study of the Predictors of Successful Management of Dyslipidemia in HIV-Infected Patients on ART: the Swiss HIV Cohort Study. <i>HIV Clinical Trials</i> , 2007, 8, 77-85.	2.0	8
275	Increased Epstein-Barr virus-specific antibody-levels in HIV-infected individuals developing primary central nervous system lymphoma. <i>Aids</i> , 2007, 21, 1664-1666.	2.2	4
276	Two versus three-class antiretroviral therapy in antiretroviral-naïve patients in different time periods of the HAART era. <i>Aids</i> , 2007, 21, 537-538.	2.2	1
277	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. <i>Aids</i> , 2007, 21, 2201-2207.	2.2	7
278	TB in a Low-Incidence Country: Differences Between New Immigrants, Foreign-Born Residents and Native Residents. <i>American Journal of Medicine</i> , 2007, 120, 350-356.	1.5	42
279	Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. <i>PLoS ONE</i> , 2007, 2, e173.	2.5	31
280	Late presentation of HIV-infected individuals. <i>Antiviral Therapy</i> , 2007, 12, 841-51.	1.0	27
281	Late Presentation of HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2007, 12, 841-851.	1.0	49
282	Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007, 12, 931-940.	1.0	26
283	CD4 <sup>+</sup> T-Cell Count Increase in HIV-1-Infected Patients with Suppressed Viral Load Within 1 year after start of antiretroviral therapy. <i>Antiviral Therapy</i> , 2007, 12, 889-898.	1.0	27
284	Immunological recovery and antiretroviral therapy in HIV-1 infection. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 280-287.	9.1	220
285	Clinical spectrum of the immune restoration inflammatory syndrome. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 56-61.	3.8	11
286	Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study. <i>Aids</i> , 2006, 20, 129-131.	2.2	7
287	Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2006, 80, 11094-11104.	3.4	103
288	A Longitudinal Analysis of Healthcare Costs after Treatment Optimization following Genotypic Antiretroviral Resistance Testing: Does Resistance Testing pay off?. <i>Antiviral Therapy</i> , 2006, 11, 305-314.	1.0	10

#	ARTICLE	IF	CITATIONS
289	Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2006, 11, 131-142.	1.0	35
290	A Smoking Cessation Programme in HIV-Infected Individuals: A Pilot Study. <i>Antiviral Therapy</i> , 2006, 11, 787-796.	1.0	63
291	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. <i>Aids</i> , 2005, 19, 1987-1994.	2.2	29
292	Symptom Management in HIV/AIDS. <i>Advances in Nursing Science</i> , 2005, 28, 333-344.	1.1	45
293	Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ÅL in HIV Type 1-Infected Individuals Receiving Potent Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 41, 361-372.	5.8	285
294	Contrary to HIV, hepatitis C virus is not associated with erythrocytes in vivo. <i>Journal of Hepatology</i> , 2005, 42, 150-152.	3.7	2
295	Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005, 10, 585-591.	1.0	95
296	Body Fat Changes among Antiretroviral-Naive Patients on Pi- and Nnrti-Based Haart in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005, 10, 73-81.	1.0	30
297	Intranasal Influenza Vaccine in a Working Population. <i>Clinical Infectious Diseases</i> , 2004, 38, 974-980.	5.8	36
298	Editorial Commentary: Sexual Risk Behavior in HIV-Infected Injection Drug Users. <i>Clinical Infectious Diseases</i> , 2004, 38, 1175-1177.	5.8	9
299	Acute Renal Failure on Immune Reconstitution in an HIV-Positive Patient with Miliary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2004, 38, e32-e35.	5.8	60
300	Protease inhibitor-sparing simplified maintenance therapy: a need for perspective. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 303-305.	3.0	7
301	Immune Reconstitution in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2004, 38, 1159-1166.	5.8	321
302	Carriage of <i>Staphylococcus aureus</i> Among Injection Drug Users: Lower Prevalence in an Injection Heroin Maintenance Program Than in an Oral Methadone Program. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 133-137.	1.8	19
303	The decision to get vaccinated against influenza. <i>American Journal of Medicine</i> , 2004, 116, 856-858.	1.5	11
304	Chest pain after travel to the tropics. <i>Lancet, The</i> , 2004, 363, 1198.	13.7	10
305	Productivity costs and determinants of productivity in HIV-infected patients. <i>Clinical Therapeutics</i> , 2004, 26, 791-800.	2.5	26
306	The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients. <i>Aids</i> , 2004, 18, 1521-1527.	2.2	29

#	ARTICLE	IF	CITATIONS
307	Is unsafe sexual behaviour increasing among HIV-infected individuals?. <i>Aids</i> , 2004, 18, 1707-1714.	2.2	31
308	Gynecomastia and potent antiretroviral therapy. <i>Aids</i> , 2004, 18, 1347-1349.	2.2	14
309	All cause mortality in the Swiss HIV cohort study from 1990 to 2001 in comparison with the Swiss population. <i>Aids</i> , 2004, 18, 1835-1843.	2.2	75
310	Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma. <i>Antiviral Therapy</i> , 2004, 9, 453-9.	1.0	2
311	Epstein-Barr Virus Load Correlating with Clinical Manifestation and Treatment Response in a Patient with Angioimmunoblastic T-Cell Lymphoma. <i>Antiviral Therapy</i> , 2004, 9, 453-459.	1.0	14
312	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004, 9, 263-274.	1.0	11
313	Infrequent Transmission of HIV-1 Drug-Resistant Variants. <i>Antiviral Therapy</i> , 2004, 9, 375-384.	1.0	59
314	Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. <i>Lancet</i> , The, 2003, 362, 877-878.	13.7	101
315	Intravenous opiate maintenance in a cohort of injecting drug addicts. <i>Drug and Alcohol Dependence</i> , 2003, 69, 183-188.	3.2	13
316	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study. <i>Aids</i> , 2003, 17, 2237-2244.	2.2	76
317	Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. <i>Aids</i> , 2003, 17, 2451-2459.	2.2	49
318	Evaluation of unstructured medical school examinations: prospective observational study. <i>Swiss Medical Weekly</i> , 2003, 133, 184-7.	1.6	4
319	Infections Requiring Hospitalization of Injection Drug Users Who Participated in an Injection Opiate Maintenance Program. <i>Clinical Infectious Diseases</i> , 2002, 34, 711-713.	5.8	26
320	Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 1303-1313.	4.1	6
321	Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. <i>Lancet</i> , The, 2002, 359, 2230-2234.	13.7	76
322	Inflammatory Bowel Perforation During Immune Restoration After One Year of Antiretroviral and Antituberculous Therapy in an HIV-1-Infected Patient. <i>Diseases of the Colon and Rectum</i> , 2002, 45, 977-978.	1.3	30
323	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. <i>Aids</i> , 2002, 16, 1967-1969.	2.2	107
324	Evidence for prevention and screening: recommendations in adults. <i>Swiss Medical Weekly</i> , 2002, 132, 363-73.	1.6	7

#	ARTICLE	IF	CITATIONS
325	Onset and pattern of substance use in intravenous drug users of an opiate maintenance program. <i>Drug and Alcohol Dependence</i> , 2001, 64, 105-109.	3.2	22
326	Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. <i>Lancet</i> , The, 2001, 358, 1322-1327.	13.7	317
327	Critical issues of HIV treatment in the era of highly active antiretroviral therapy. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 175-183.	4.1	4
328	Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. <i>Aids</i> , 2000, 14, 791-799.	2.2	36
329	Discontinuation of Primary Prophylaxis against <i>Pneumocystis carinii</i> Pneumonia in HIV-1 Infected Adults Treated with Combination Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 1999, 340, 1301-1306.	27.0	271
330	Cost-effectiveness of azithromycin for preventing <i>Mycobacterium avium</i> complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 811-817.	3.0	27
331	AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 2220.	7.4	416
332	General and specific immunosuppression caused by antiviral T-cell responses. <i>Immunological Reviews</i> , 1999, 168, 305-315.	6.0	49
333	Salvage treatment against human immunodeficiency virus. <i>Annals of Medicine</i> , 1999, 31, 253-260.	3.8	9
334	Downregulation of Bcl-2, but Not of Bax or Bcl-x, Is Associated with T Lymphocyte Apoptosis in HIV Infection and Restored by Antiretroviral Therapy or by Interleukin 2. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 803-810.	1.1	38
335	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. <i>Lancet</i> , The, 1999, 353, 863-868.	13.7	894
336	Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. <i>Aids</i> , 1999, 13, 501-507.	2.2	237
337	Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. <i>Aids</i> , 1999, 13, 1587.	2.2	24
338	HIV-1-infected patients with focal neurologic signs: diagnostic role of PCR for <i>Toxoplasma gondii</i> , Epstein-Barr virus, and JC virus. <i>Clinical Microbiology and Infection</i> , 1998, 4, 577-584.	6.0	28
339	Is CD95 or CD26 expression on T-cells a marker for HIV non- or slow-progressor status?. <i>Clinical Microbiology and Infection</i> , 1998, 4, 464-465.	6.0	0
340	Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. <i>FEBS Journal</i> , 1998, 254, 514-519.	0.2	68
341	Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. <i>Aids</i> , 1998, 12, 2115-2123.	2.2	89
342	Genotype distribution of hepatitis C virus infection in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 75-80.	1.6	12

#	ARTICLE	IF	CITATIONS
343	Does Pregnancy Influence the Course of HIV Infection? Evidence from Two Large Swiss Cohort Studies. <i>Obstetrical and Gynecological Survey</i> , 1998, 53, 671-672.	0.4	0
344	High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. <i>Journal of Hepatology</i> , 1997, 26, 794-797.	3.7	57
345	Low doses of zidovudine plus didanosine are less effective than higher doses of didanosine monotherapy: a randomized trial in patients pretreated with zidovudine. <i>Clinical Microbiology and Infection</i> , 1997, 3, 629-633.	6.0	0
346	Erythema of the proximal nailfold in HIV-infected patients. <i>Journal of the American Academy of Dermatology</i> , 1996, 35, 631-633.	1.2	36
347	Antiviral Immune Responses of Mice Lacking MHC Class II or Its Associated Invariant Chain. <i>Cellular Immunology</i> , 1996, 167, 115-121.	3.0	51
348	Non-tolerant B cells cause autoimmunity in anti-CD8 IgG2a-transgenic mice. <i>European Journal of Immunology</i> , 1996, 26, 250-258.	2.9	13
349	Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. <i>Digestive Diseases and Sciences</i> , 1995, 40, 1583-1588.	2.3	36
350	Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. <i>Journal of Medical Virology</i> , 1994, 44, 389-392.	5.0	41
351	Hepatitis delta virus RNA in serum of patients with chronic delta hepatitis. <i>Digestive Diseases and Sciences</i> , 1994, 39, 2650-2655.	2.3	9
352	Lysis of infected cells in vivo by antiviral cytolytic T cells demonstrated by release of cell internal viral proteins. <i>European Journal of Immunology</i> , 1993, 23, 1540-1545.	2.9	23
353	Enhancement of disease by neutralizing antiviral antibodies in the absence of primed antiviral cytotoxic T cells. <i>European Journal of Immunology</i> , 1993, 23, 3236-3241.	2.9	40
354	Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. <i>Journal of Virological Methods</i> , 1991, 33, 191-198.	2.1	446
355	Exploring the Doctor-Patient Relationship Reduces Staff Stress and Enhances Empathy When Caring for AIDS Patients. <i>Psychotherapy and Psychosomatics</i> , 1991, 56, 167-173.	8.8	8